330 related articles for article (PubMed ID: 33273056)
1. An Anti-CD22-
Yu SF; Lee DW; Zheng B; Del Rosario G; Leipold D; Booler H; Zhong F; Carrasco-Triguero M; Hong K; Yan P; Rowntree RK; Schutten MM; Pillow T; Sadowsky JD; Dragovich PS; Polson AG
Mol Cancer Ther; 2021 Feb; 20(2):340-346. PubMed ID: 33273056
[TBL] [Abstract][Full Text] [Related]
2. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Advani RH; Lebovic D; Chen A; Brunvand M; Goy A; Chang JE; Hochberg E; Yalamanchili S; Kahn R; Lu D; Agarwal P; Dere RC; Hsieh HJ; Jones S; Chu YW; Cheson BD
Clin Cancer Res; 2017 Mar; 23(5):1167-1176. PubMed ID: 27601593
[No Abstract] [Full Text] [Related]
4. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.
Pfeifer M; Zheng B; Erdmann T; Koeppen H; McCord R; Grau M; Staiger A; Chai A; Sandmann T; Madle H; Dörken B; Chu YW; Chen AI; Lebovic D; Salles GA; Czuczman MS; Palanca-Wessels MC; Press OW; Advani R; Morschhauser F; Cheson BD; Lenz P; Ott G; Polson AG; Mundt KE; Lenz G
Leukemia; 2015 Jul; 29(7):1578-86. PubMed ID: 25708834
[TBL] [Abstract][Full Text] [Related]
5. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Li D; Poon KA; Yu SF; Dere R; Go M; Lau J; Zheng B; Elkins K; Danilenko D; Kozak KR; Chan P; Chuh J; Shi X; Nazzal D; Fuh F; McBride J; Ramakrishnan V; de Tute R; Rawstron A; Jack AS; Deng R; Chu YW; Dornan D; Williams M; Ho W; Ebens A; Prabhu S; Polson AG
Mol Cancer Ther; 2013 Jul; 12(7):1255-65. PubMed ID: 23598530
[TBL] [Abstract][Full Text] [Related]
6. Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response.
Dela Cruz Chuh J; Go M; Chen Y; Guo J; Rafidi H; Mandikian D; Sun Y; Lin Z; Schneider K; Zhang P; Vij R; Sharpnack D; Chan P; de la Cruz C; Sadowsky J; Seshasayee D; Koerber JT; Pillow TH; Phillips GD; Rowntree RK; Boswell CA; Kozak KR; Polson AG; Polakis P; Yu SF; Dragovich PS; Agard NJ
MAbs; 2021; 13(1):1862452. PubMed ID: 33382956
[TBL] [Abstract][Full Text] [Related]
7. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.
Li D; Lee D; Dere RC; Zheng B; Yu SF; Fuh FK; Kozak KR; Chung S; Bumbaca Yadav D; Nazzal D; Danilenko D; Go MAT; Williams M; Polson AG; Poon KA; Prabhu S
Br J Pharmacol; 2019 Oct; 176(19):3805-3818. PubMed ID: 31270798
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.
Fuh FK; Looney C; Li D; Poon KA; Dere RC; Danilenko DM; McBride J; Reed C; Chung S; Zheng B; Mathews WR; Polson A; Prabhu S; Williams M
Br J Pharmacol; 2017 Apr; 174(8):628-640. PubMed ID: 28009435
[TBL] [Abstract][Full Text] [Related]
9. Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.
Chen Y; Samineni D; Mukadam S; Wong H; Shen BQ; Lu D; Girish S; Hop C; Jin JY; Li C
Clin Pharmacokinet; 2015 Jan; 54(1):81-93. PubMed ID: 25223698
[TBL] [Abstract][Full Text] [Related]
10. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
11. Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
Mehta A; Forero-Torres A
Curr Oncol Rep; 2015 Sep; 17(9):41. PubMed ID: 26194424
[TBL] [Abstract][Full Text] [Related]
12. Monomethyl Auristatin E (MMAE), a Payload for Multiple Antibody Drug Conjugates (ADCs), Demonstrates Differential Red Blood Cell Partitioning Across Human and Animal Species.
Yip V; Saad OM; Leipold D; Li C; Kamath A; Shen BQ
Xenobiotica; 2024 Apr; ():1-13. PubMed ID: 38647387
[No Abstract] [Full Text] [Related]
13. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.
Bourbon E; Salles G
Expert Opin Investig Drugs; 2020 Oct; 29(10):1079-1088. PubMed ID: 32700972
[TBL] [Abstract][Full Text] [Related]
14. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
[TBL] [Abstract][Full Text] [Related]
15. The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity.
Abuhay M; Kato J; Tuscano E; Barisone GA; Sidhu RS; O'Donnell RT; Tuscano JM
Cancer Immunol Immunother; 2016 Oct; 65(10):1169-75. PubMed ID: 27506529
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.
Polson AG; Williams M; Gray AM; Fuji RN; Poon KA; McBride J; Raab H; Januario T; Go M; Lau J; Yu SF; Du C; Fuh F; Tan C; Wu Y; Liang WC; Prabhu S; Stephan JP; Hongo JA; Dere RC; Deng R; Cullen M; de Tute R; Bennett F; Rawstron A; Jack A; Ebens A
Leukemia; 2010 Sep; 24(9):1566-73. PubMed ID: 20596033
[TBL] [Abstract][Full Text] [Related]
17. Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody-Drug Conjugates.
Bordeau BM; Nguyen TD; Polli JR; Chen P; Balthasar JP
Mol Cancer Ther; 2023 Apr; 22(4):459-470. PubMed ID: 36723609
[TBL] [Abstract][Full Text] [Related]
18. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
Lambert JM; Morris CQ
Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.
Dornan D; Bennett F; Chen Y; Dennis M; Eaton D; Elkins K; French D; Go MA; Jack A; Junutula JR; Koeppen H; Lau J; McBride J; Rawstron A; Shi X; Yu N; Yu SF; Yue P; Zheng B; Ebens A; Polson AG
Blood; 2009 Sep; 114(13):2721-9. PubMed ID: 19633198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
